Predictive data of eligibility and stability of TFR19,39
| Parameter . | Impact on eligibility for TFR . | Impact on stability of TFR . | Study examples . |
|---|---|---|---|
| Prognostic score | DMR more frequent in low-risk patients | TFR more stable in low-risk patients; risk of relapse high in high-risk patients | STIM, STIM2, ENESTfreedom, TWISTER |
| TKI type | DMR more frequent with 2G-TKIs vs imatinib | No major difference | |
| Initial slope of BCR-ABL1 transcript decline or “halving time” | Probability of DMR better in patients with EMR | No major difference | |
| MMR at 12 months | Probability of DMR better in patients with MMR | No major difference | |
| Type of BCR-ABL1 transcript | DMR more likely in patients with e14a2 vs e13a2 (inconsistent) | TFR more stable with e14a2 (inconsistent) | |
| Mutations outside BCR-ABL1 | MMR and DMR more likely in patients lacking BCR-ABL1- independent mutations | Data still immature | |
| Duration of DMR | Longer DMR predictive | EURO-SKI | |
| Level of MR before stop | Probably yes; undetectable BCR-ABL1 predictive | EURO-SKI, ENESTfreedom | |
| Duration of TKI therapy | Inconsistent, overlapping with duration of DMR | STIM | |
| Proportion of natural killer cells | Reduced risk of relapse after imatinib and dasatinib but not after nilotinib |
| Parameter . | Impact on eligibility for TFR . | Impact on stability of TFR . | Study examples . |
|---|---|---|---|
| Prognostic score | DMR more frequent in low-risk patients | TFR more stable in low-risk patients; risk of relapse high in high-risk patients | STIM, STIM2, ENESTfreedom, TWISTER |
| TKI type | DMR more frequent with 2G-TKIs vs imatinib | No major difference | |
| Initial slope of BCR-ABL1 transcript decline or “halving time” | Probability of DMR better in patients with EMR | No major difference | |
| MMR at 12 months | Probability of DMR better in patients with MMR | No major difference | |
| Type of BCR-ABL1 transcript | DMR more likely in patients with e14a2 vs e13a2 (inconsistent) | TFR more stable with e14a2 (inconsistent) | |
| Mutations outside BCR-ABL1 | MMR and DMR more likely in patients lacking BCR-ABL1- independent mutations | Data still immature | |
| Duration of DMR | Longer DMR predictive | EURO-SKI | |
| Level of MR before stop | Probably yes; undetectable BCR-ABL1 predictive | EURO-SKI, ENESTfreedom | |
| Duration of TKI therapy | Inconsistent, overlapping with duration of DMR | STIM | |
| Proportion of natural killer cells | Reduced risk of relapse after imatinib and dasatinib but not after nilotinib |
EMR, early molecular response.